HR+/HER2- Breast cancer epidemiology: How the prevalence is changing the population trends?

HR-positive/HER2-negative breast cancer is the most prevalent form of breast cancer disease. This type reports having a higher percentage among all breast cancers. 

HR positive/ HER2 negative breast cancer market

Hormone receptors (HR) are the proteins, which receive hormone signals and command the cancer cells to proliferate. If the breast cancer cells receive signals from the hormone estrogen that could promote tumour growth, then it is called as estrogen receptor-positive (ER+) breast cancer. If cancerous cells receive the signals from the hormone progesterone that could spur the growth, it is called progesterone receptor-positive (PR+) breast cancer. Also, human epidermal growth factor receptor 2 (HER2) is a gene that aids in controlling how cells grow, divide, and repair themselves.

 

Many women have breast cancer globally; the prevalence is increasing every day. DelveInsight has reported that the total Breast Cancer incident population in the 7MM is expected to grow at CAGR of 0.83%, during the study period [2017–2028] in their epidemiology model for HR-positive/ HER2-negative Breast Cancer market report.

HR positive/ HER2 negative breast cancer market epidemiology

It was also reported that the United States show a higher incidence of Breast Cancer in the United States with 266,120 cases in 2017. Among the EU-5 countries, Germany ranked first with 71,585 cases in 2017, followed by Italy, and France, in 2017. On the other hand, Spain has the least number of breast cancer incident cases which was equivalent to 11.99% of the total EU-5 breast cancer cases.  

 

While taking into account of Japan, it accounts for the second-highest breast cancer incident cases among the 7MM countries. In 2017, it was observed that the incident population of breast cancer in Japan was found to be 89,100, which was equivalent to 14.21% of the total breast cancer incident population.

In all other 7MM countries, excluding Japan, among the various subtypes of the disease, HR-positive/HER2-negative occupies the maximum patient pool, followed by the number of those with Triple-negative and HR-positive/HER2-positive. On the other hand, HR-negative/HER2-positive accommodated the least number of cases. Furthermore, from the category of HR-positive/HER2-negative, ER+ is primarily responsible for HR-positive cases.

DelveInsight’s HR-positive/HER2-negative breast cancer market research report has included Epidemiology Segmentation (7MM for 2017–2028) as Total Incident cases of Breast Cancer in the 7MM, Breast Cancer Incidence Cases by Menopausal Status, Stage Specific Incidence of Breast Cancer in Post-Menopausal Women, Stage Specific Diagnosed Incidence of Breast Cancer in Post- Menopausal Women, Diagnosed Incidence of Early Stage Breast Cancer in Postmenopause by Molecular Subtype, Diagnosed Incidence of Locally Advanced and Metastatic Breast Cancer in Postmenopause by Molecular Subtypes. The market report proffers the exhaustive epidemiological trends and epidemiology forecast covering the seven major markets.